MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is developing an AI-powered voice analysis platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional testing methods. The technology, trained on more than 50 million data points and analyzing over 140 acoustic markers, aims to deliver real-time impairment assessments through Edge AI kiosks. Initial field testing is planned for 2026, with an initial commercial focus on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges.
According to the company, the global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033. MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers, and healthcare, leveraging its proprietary research to address the increasing demand for faster, scalable workplace impairment detection. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice.
MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction, and law enforcement.
The potential impact of this technology is significant. Traditional impairment testing methods, such as breath, saliva, urine, and laboratory-based tests, can be invasive, time-consuming, and logistically challenging for large workforces. MindBio's voice-based AI platform offers a non-invasive, real-time alternative that could streamline safety protocols and reduce downtime in industries where impairment poses serious risks. For example, in mining operations, where workers often operate heavy machinery in remote locations, rapid and accurate impairment detection could prevent accidents and save lives.
The technology also addresses the growing need for scalable solutions as the market for alcohol and drug testing devices expands. With projections indicating a near-doubling of the market size over the next eight years, MindBio's platform could become a key tool for employers seeking to comply with safety regulations and maintain productive work environments. The company's initial focus on South American mining operations underscores the practical challenges of workforce screening in remote, large-scale settings, where traditional methods are often impractical.
For further information, the latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF. The full article detailing this announcement can be accessed at https://ibn.fm/Gw5Fa.
